Breaking News Headlines Today | Ground News

See every side of every news story

curetoday.com image

News from curetoday.com

We’ve assigned a media bias rating of unknown to curetoday.com. You can read more about our methodology here.

curetoday.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about curetoday.com

Where is curetoday.com located?curetoday.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top curetoday.com News

FDA Grants Priority Review to AZ's Datroway for Metastatic Triple Negative Breast Cancer

FDA · United States

FDA Grants Priority Review to AZ's Datroway for Metastatic Triple Negative Breast Cancer

60% Center coverage: 5 sources

FDA has granted priority review to AstraZeneca's Datroway for the first-line treatment of metastatic TNBC treatment.See the Story

TuHURA Biosciences Received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

United States · United States

TuHURA Biosciences Received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

TuHURA Biosciences, Inc. announced that the US FDA Office of Orphan Products Development has granted Orphan Drug Designation to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma. [TuHURA Biosciences, Inc.] Press Release See the Story

CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

New data reveals CD47 expression as a key biomarker for predicting evorpacept's effectiveness in treating HER2-positive metastatic breast cancer.See the Story

Breaking News Topics Related to curetoday.com